Vericel Corporation (VCEL) & KalVista Pharmaceuticals (KALV) Financial Analysis

Vericel Corporation (NASDAQ: VCEL) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Analyst Recommendations

This is a breakdown of current ratings for Vericel Corporation and KalVista Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel Corporation 0 0 3 0 3.00
KalVista Pharmaceuticals 0 0 1 0 3.00

Vericel Corporation currently has a consensus target price of $6.33, suggesting a potential upside of 39.19%. KalVista Pharmaceuticals has a consensus target price of $27.00, suggesting a potential upside of 112.10%. Given KalVista Pharmaceuticals’ higher possible upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Vericel Corporation.

Earnings and Valuation

This table compares Vericel Corporation and KalVista Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Vericel Corporation $53.77 million 2.78 -$20.03 million ($1.10) -4.14
KalVista Pharmaceuticals $625,000.00 197.83 -$16.21 million N/A N/A

KalVista Pharmaceuticals has higher revenue, but lower earnings than Vericel Corporation.

Insider and Institutional Ownership

34.0% of Vericel Corporation shares are owned by institutional investors. Comparatively, 75.7% of KalVista Pharmaceuticals shares are owned by institutional investors. 3.3% of Vericel Corporation shares are owned by company insiders. Comparatively, 49.1% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


This table compares Vericel Corporation and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel Corporation -50.27% N/A -59.46%
KalVista Pharmaceuticals -4,191.47% -60.42% -55.11%

Volatility and Risk

Vericel Corporation has a beta of 3.16, meaning that its share price is 216% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.


KalVista Pharmaceuticals beats Vericel Corporation on 6 of the 11 factors compared between the two stocks.

About Vericel Corporation

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

What are top analysts saying about Vericel Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vericel Corporation and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit